THE EXPLORATION OF ETIOLOGICAL STRUCTURE OF SEXUALLY TRANSMITTED DISEASES IN PATIENTS OF ONCOLOGIC INSTITUTE

Cover Page

Cite item

Full Text

Abstract

The attention to the problem of studying etiologic structure and patterns of prevalence of sexually transmitted infections is conditioned by their high morbidity, affection of population of reproductive age mainly and aftermath effecting health of people and their posterity. The polymerase chain reaction in real-time was applied to detect DNA of agents of sexually transmitted diseases in patients with inflammatory and oncologic diseases of urogenital tract. It was established that 55.4% of patients (64.6% females and 35.0% males) were infected by agents from group of sexually transmitted diseases. The mixed infections made up to 53.0% (54.9% females and 45.5% males). The index of prevalence of C. trachomatis in total cohort of examined individuals is equal to 2.2%. The age and gender differences were established concerning rate of detection of DNA of agents of sexually transmitted diseases. The DNA of C. trachomatis and viruses of herpes simplex type I and II was registered more often in males and the DNA of U. parvum/urealyticum, G. vaginalis, M. hominis, Candida spp. and cytomegalovirus - in females. The decreasing of amount of total bacterial mass and lactobacteria was established in all female patients with oncologic diseases. In females of this group the index of total prevalence of urogenital infections is 1.4 times lower than in group with inflammatory pathologies. The rate of mixed infections has factually no differences (52.9% and 55.2% correspondingly) and the level of detection of DNA of virus of human papilloma against the background of sexually transmitted diseases on the contrary is 1.7 times higher. In females being in menopause period total prevalence of agents of sexually transmitted diseases and rate of mixed infections were lower than in female patients of reproductive age.

About the authors

G. A. Nerodo

Rostov Research Institute of Oncology

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

T. A. Zykova

Rostov Research Institute of Oncology

Email: tatiana2904@yandex.ru
Russian Federation

M. N. Duritskiy

Rostov Research Institute of Oncology

Email: noemail@neicon.ru
Russian Federation

V. A. Sustretov

Rostov Research Institute of Oncology

Email: noemail@neicon.ru
Russian Federation

V. P. Nikitina

Rostov Research Institute of Oncology

Email: noemail@neicon.ru
Russian Federation

A. P. Men'shenina

Rostov Research Institute of Oncology

Email: noemail@neicon.ru
Russian Federation

O. A. Bogomolova

Rostov Research Institute of Oncology

Email: noemail@neicon.ru
Russian Federation

P. A. Kruze

Rostov Research Institute of Oncology

Email: noemail@neicon.ru
Russian Federation

References

  1. WHO. Global health sector strategy on sexually transmitted infections. Towards ending STIs. Geneva; 2016. Available at: http://apps.who.int/iris/bitstream/10665/246296/1/WHO-RHR-16.09-eng.pdf
  2. Поршина О.В., Полев А.В., Романова О.В., Шаповалов В.С. Современная ситуация по возрастным и гендерным характеристикам больных инфекциями, передающимися половым путем. Здравоохранение Российской Федерации. 2013; 57(3): 39-42.
  3. Киясов И.А., Хузиханов Ф.В. Современные тенденции заболеваемости инфекциями, передающимися половым путем, и пути ее профилактики. Успехи современного естествознания. 2015; (2): 51-5.
  4. Kohl K.S., Markowitz L.E., Koumans E.H. Developments in the screening for Chlamydia trachomatis: a review. Obstet. Gynecol. Clin. North. Am. 2003; 30(4): 637-58.
  5. Gottlieb S.L., Martin D.H., Xu F. Summary: The Natural History and Immunobiology of Chlamydia trachomatis Genital Infection and Implications for Chlamydia Control. J. Infect. Dis. 2010; 201: S190-204.
  6. Workowski K.A., Berman S. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR Recomm. Rep. 2010; 59(RR-12): 1-110.
  7. Lanjouw E., Ouburg S., de Vries H.J., Stary A., Radcliffe K., Unemo M. 2015 European guideline on the management of Chlamydia trachomatis infections. Int. J. STD. AIDS. 2016; 27(5): 333-48.
  8. CDC. Sexually transmitted disease surveillance 2012. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. Available at http://www.cdc.gov/std/stats12/default.htm
  9. Torrone E., Papp J., Weinstock H. Centers for Disease Control and Prevention (CDC). Prevalence of Chlamydia trachomatis Genital Infection Among Persons Aged 14-39 Years - United States, 2007-2012. MMWR Morb. Mortal. Wkly Rep. 2014; 63(38): 834-8.
  10. Wallin K.L., Wiklund F., Luostarinen T., Angström T., Anttila T., Bergman F., et al. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int. J. Cancer. 2002, 101(4): 371-4.
  11. Wiesenfeld H.C., Sweet R.L., Ness R.B., Krohn M.A., Amortegui A.J., Hillier S.L. Comparison of acute and subclinical pelvic inflammatory disease. Sex. Transm. Dus. 2005; 32(7): 400-5.
  12. Brunham R.C., Gottlieb S.L., Paavonen J. Pelvic inflammatory disease. N. Engl. J. Med. 2015; 372(21): 2039-48.
  13. Stamm WE. Chlamydia trachomatis infections in the adult. In: Holmes K.K., Sparling P.F., Stamm W.E., Piot P., Wasserheit J., Corey L., et al. Sexually transmitted diseases. 4th edition. New York: McGraw-Hill; 2008: 575-93.
  14. ВОЗ. Интегрирование ИППП/ИРТ в репродуктивное здоровье. Инфекции, передаваемые половым путем и иные инфекции репродуктивного тракта. Женева; 2004.
  15. WHO. Global strategy for the prevention and control of sexually transmitted infections: 2006-2015: breaking the chain of transmission. Geneva; 2007.
  16. Унанян А.Л., Коссович Ю.М. Хронический цервицит: особенности этиологии, патогенеза, диагностики и лечения. Российский вестник акушера-гинеколога. 2012; 12(6): 40-5.
  17. Пестрикова Т.Ю., Панфилова Ю.О. Чувствительность патогенной микрофлоры цервикального канала к антибактериальным препаратам у пациенток с хроническим цервицитом и вирусом папилломы человека. Гинекология. 2015; 17(1): 18-21.
  18. Мальцева Л.И., Фаррахова Л.Н. Особенности лечения ВПЧ-ассоциированного цервицита. Эффективная фармакотерапия. 2013; (8): 42-8.
  19. Philip M., Rowley D.A., Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin. Cancer Biol. 2009; 14(6): 433-9.
  20. Albini A., Tosetti F., Benelli R., Noonan D.M. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res. 2005; 65(23): 10637-41.
  21. Бандовкина В.А., Франциянц Е.М., Моисеенко Т.И., Вовкочина М.А., Адамян М.Л., Комарова Е.Ф., Черярина Н.Д., Зыкова Т.А. Уровень гормонов в ткани рака тела матки и интактных яичниках ассоциированный с различными вирусными инфекциями. Злокачественные опухоли. 2014; (3): 9-14.
  22. Бандовкина В.А., Франциянц Е.М., Моисеенко Т.И., Вовкочина М.А., Адамян М.Л., Комарова Е.Ф., Черярина Н.Д., Зыкова Т.А. Инфекционные агенты как модулирующие факторы синтеза гормонов de novo в опухолевой ткани у больных раком тела матки. Молекулярная медицина. 2016; 14 (1): 45-9.
  23. Роговская С.И., Липова Е.В., ред. Шейка матки, влагалище, вульва: физиология, патология, кольпоскопия, эстетическая коррекция. М.: StatusPraesens; 2014.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Nerodo G.A., Zykova T.A., Duritskiy M.N., Sustretov V.A., Nikitina V.P., Men'shenina A.P., Bogomolova O.A., Kruze P.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:  ПИ № ФС77-50668 от 13.07.2012 г.